ArticleCirculation. Heart failure2026
Decoding the Heart Failure Peptidome.
Article in Circulation. Heart failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPeptides such as angiotensin II and brain natriuretic peptide are pivotal in diagnosing and treating heart failure (HF). However, unbiased systematic studies of the peptidome in patients with HF are lacking. Deciphering the plasma peptidome might significantly improve the diagnosis, prognostication, and treatment of patients with HF.
methodsTo systematically explore the low molecular peptidome, we conducted a cross-sectional mass spectrometry analysis from 486 patients with HF and 98 age-matched non-HF controls. We quantified 21 694 unique peptides in plasma, which were ranked according to (1) the relative upregulation in HF versus controls, (2) pattern similarity to bioactive peptides by an adapted machine learning method, and (3) association with clinical outcome.
resultsWe observed 1924 differentially expressed peptides between patients with HF and non-HF controls. Among high-ranking peptides in patients with HF were angiotensin-related peptides (eg, angiotensin 1-9), propeptides from GIP (gastric inhibitory polypeptide), osteocalcin and cholecystokinin, and peptides mapping to the extracellular part of the natriuretic peptide clearance receptor and integrin alpha-7. Among the regulated peptides, 141 were scored in the top 5% by our machine learning approach, and 65 peptides herein were independently associated with clinical outcome. A hierarchical clustering analysis of patients with HF revealed 3 major patient clusters based on the peptide signature. The patient cluster with the lowest survival probability exhibited a specific peptide degradation pattern with a higher proportion of peptides linked to the acute phase response and increased inflammation.
conclusionsThis study uniquely identifies peptides according to their regulation and likelihood of being a bioactive peptide in patients with HF compared with non-HF controls. The study provides crucial peptide-level information to complement protein-based methodologies. The most promising peptides were related to the renin-angiotensin system, natriuretic peptides, and cardiometabolic regulation. The stepwise ranking highlights the HF peptide signal important for outcome and provides a rich resource for additional exploration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.